(Total Views: 594)
Posted On: 10/17/2017 12:13:22 PM
Post# of 124
Nice jump today
i sent an email to the company asking about Nasdaq listing and potential outlicensing or co-promotion of Natesto below is the answer from Josh disbrow (ceo) . And there was more good news for AYTU because Antares (ATRS) who has also a Testosterone Product close to Approval got a FDA letter so Approval is may unlikely on october 20 link to full story see below .
Hi xxxxxx
Thanks for your email. We now have a strong cash balance following our $11.8M private placement that closed on August 15th. We expect to uplist to NASDAQ in the very near term, and that process is well underway. We have initiated substantial IR over the last 6 weeks and, with the registration of the shares recently placed, we expect to see a significant increase in our market float and trading volume. We have a strong sales team of 35 sales representatives calling on the top 7,000 TRT prescribers. That said, we are always open to exploring relationships through which we can further enhance our presence. That said, prescriptions for Natesto continue to reach all time high levels. We are very pleased with the progress.
Thanks for your interest in AYTU.
Best,
Josh
With Antares Pharma’s (ATRS) Xyosted DOA, Is Aytu BioScience (AYTU) The Beneficiary?
cnafinance.com/with-antares-pharmas-atrs-xyosted-doa-is-aytu-bioscience-aytu-the-beneficiary/16792
i sent an email to the company asking about Nasdaq listing and potential outlicensing or co-promotion of Natesto below is the answer from Josh disbrow (ceo) . And there was more good news for AYTU because Antares (ATRS) who has also a Testosterone Product close to Approval got a FDA letter so Approval is may unlikely on october 20 link to full story see below .
Hi xxxxxx
Thanks for your email. We now have a strong cash balance following our $11.8M private placement that closed on August 15th. We expect to uplist to NASDAQ in the very near term, and that process is well underway. We have initiated substantial IR over the last 6 weeks and, with the registration of the shares recently placed, we expect to see a significant increase in our market float and trading volume. We have a strong sales team of 35 sales representatives calling on the top 7,000 TRT prescribers. That said, we are always open to exploring relationships through which we can further enhance our presence. That said, prescriptions for Natesto continue to reach all time high levels. We are very pleased with the progress.
Thanks for your interest in AYTU.
Best,
Josh
With Antares Pharma’s (ATRS) Xyosted DOA, Is Aytu BioScience (AYTU) The Beneficiary?
cnafinance.com/with-antares-pharmas-atrs-xyosted-doa-is-aytu-bioscience-aytu-the-beneficiary/16792
(0)
(0)
